Personalized immune testing study for bowel and transplant patients
Part of Digestive system, Immune system & allergy clinical trials.
This study looks at whether a precise lab test can help understand inflammatory bowel disease, functional gut disorders, and immune changes after stem cell transplant or cell therapy. It may help doctors choose better monitoring and treatments based on your immune and gut test results.
Summary written for real people, not researchers, by Clin2.
Who can take part
- If you’re in the IBD/FGID group: be at least 6 years old and weigh at least 10 kg (about 22 lb)
- If you’re in the transplant or cell-therapy group (or their donors): be at least 1 month old and weigh at least 3 kg (about 6.6 lb)
- If you’re in the healthy blood volunteer group: be 18+ with no current illness, no known immune system disease, and not taking immune-suppressing medicines
- If you’re a donor or a household member: be older than 1 year and weigh more than 3 kg, and agree to participate by signing consent
- You (and/or a parent or legal guardian) must sign written informed consent to take part
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This feasibility study tests a technique called CLINIMACS to reduce certain immune cells (alpha/beta T-cells) before a stem cell transplant. It may help make the transplant safer and better controlled, but this is an early-stage feasibility test.
This study looks at immune cells in your blood and in tissues affected by chronic graft-versus-host disease (a condition where donor cells attack your body) after a stem cell transplant. By analyzing samples, researchers hope to better understand this condition and improve future treatments.
This trial aims to develop a test using multiple biomarkers to predict how well patients will respond to treatment for acute graft-versus-host disease (GVHD) affecting the gut. It focuses on patients who are receiving an allogeneic stem cell transplant.
This trial studies how well a donor bone marrow (stem cell) transplant works for people with inherited immune system problems (called immune deficiencies). It’s for patients who haven’t improved with usual treatment or don’t have another good option.
This study looks for proteins or markers in your blood that could help predict a condition called chronic graft-versus-host disease (cGVHD), a common complication after a stem cell transplant from a donor. By joining, you may help doctors detect and treat this condition earlier.
This study looks at immune cells in tissues affected by chronic graft-versus-host disease (cGVHD), a common complication after a stem cell transplant. It aims to better understand the condition, which may lead to better treatments.
Hear when a new Graft Vs Host Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.